Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trialChristoph Röllig, Gerhard Ehninger, Hubert Serve et al.|The Lancet Oncology|2015Cited by 402
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trialVolker Kunzmann, Wolfgang Blau, Jens T. Siveke et al.|The Lancet. Gastroenterology & hepatology|2020Cited by 202
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trialChristoph Röllig, Hubert Serve, Richard Noppeney et al.|Leukemia|2021Cited by 58
The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml TrialChristoph Röllig, Gerhard Ehninger, Hubert Serve et al.|Blood|2017Cited by 21
Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AMLSonia Jaramillo, Richard F. Schlenk, Johannes Krisam et al.|Trials|2021Cited by 7